Compare HFRO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFRO | AURA |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.8M | 355.0M |
| IPO Year | N/A | 2021 |
| Metric | HFRO | AURA |
|---|---|---|
| Price | $6.28 | $5.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 179.8K | ★ 183.9K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.24 | $4.35 |
| 52 Week High | $6.45 | $8.27 |
| Indicator | HFRO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 52.48 |
| Support Level | $6.18 | $5.39 |
| Resistance Level | $6.30 | $5.70 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 66.67 | 74.95 |
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.